<SEC-DOCUMENT>0001193125-25-062819.txt : 20250326
<SEC-HEADER>0001193125-25-062819.hdr.sgml : 20250326
<ACCEPTANCE-DATETIME>20250325202300
ACCESSION NUMBER:		0001193125-25-062819
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250325
FILED AS OF DATE:		20250326
DATE AS OF CHANGE:		20250325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		25769789

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d936071d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as March 25, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d936071dex991.htm">First Patient Dosed in Immutep&#146;s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer</A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March 25, 2025 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d936071dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g936071g92h95.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>First Patient Dosed in Immutep&#146;s <FONT STYLE="white-space:nowrap">TACTI-004</FONT> Phase III Trial </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>in First Line <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for
Immutep </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Global Phase III with efti will enrol approximately 756 patients at more than 150 clinical sites
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Trial results will inform potential marketing approval application in
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, one of the largest indications in oncology </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA
&#150; March&nbsp;25, 2025 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the first patient
has been successfully dosed in the Company&#146;s pivotal <FONT STYLE="white-space:nowrap">TACTI-004</FONT> Phase III trial. <FONT STYLE="white-space:nowrap">TACTI-004</FONT> will evaluate Immutep&#146;s eftilagimod alfa, a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> MHC Class&nbsp;II agonist, in combination with MSD&#146;s (Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA) <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) and chemotherapy as first line treatment for patients with advanced or metastatic <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (1L NSCLC). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr.</B><B></B><B>&nbsp;Ina Nordman, who treated the first patient at Calvary
Mater Newcastle Hospital in Australia, stated</B>, &#147;We are very excited to participate in this important Phase III trial. Despite advancements in the treatment landscape for <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer,
there remains a high unmet need for new approaches that can safely extend patients&#146; lives. The anti-cancer immune response driven by efti&#146;s unique mechanism of action as an MHC Class&nbsp;II agonist in combination with KEYTRUDA has led to
strong efficacy across all <FONT STYLE="white-space:nowrap">PD-L1</FONT> levels with favourable safety in multiple lung cancer trials. We hope to see this study confirm the promise of this novel combination to provide patients with a powerful new
treatment option.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep CEO, Marc Voigt, said,</B> &#147;Dosing the first patient in our pivotal Phase III trial ranks among the most
significant milestones in the Company&#146;s history. We are excited about the potential of the <FONT STYLE="white-space:nowrap">TACTI-004</FONT> study to deliver a new
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> therapy for patients with metastatic or advanced <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer that includes efti in combination
with KEYTRUDA. If successful, the study will result in a clinically meaningful and statistically improved survival benefit and thus could potentially be practice changing.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep CSO, Fr&eacute;d&eacute;ric Triebel, M.D., Ph.D, commented,</B> &#147;As a result of all global regulatory interactions to date including previous
discussion with US FDA under Project Optimus and tolerability issues at 90 mg<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>, we are moving forward with 30 mg subcutaneous efti dosing used in previous studies. The ability of 30 mg efti in
combination with KEYTRUDA to activate the immune system and fight <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression has been demonstrated across multiple
clinical trials.<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> Importantly, this novel approach has an excellent safety profile while delivering strong efficacy that compares favourably to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">standard-of-care</FONT></FONT> therapies, including high rates of durable responses and compelling progression-free survival and overall survival.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g936071g92h95.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recruitment in <FONT STYLE="white-space:nowrap">TACTI-004</FONT> is underway at a growing number of activated
clinical sites and countries with approvals from all regulatory authorities continues to expand including Australia, Austria, Belgium, Bulgaria, Canada, Germany, Greece, Hungary, India, Ireland, Italy, Latvia, Lithuania, Portugal, Spain, and the
United Kingdom. Further regulatory clearances in three additional countries are expected shortly, with the remaining countries anticipated in the weeks and months ahead. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lung cancer is the leading cause of death among all cancer types and the incidence is set to increase to approximately 3&nbsp;million cases worldwide by 2030.<SUP
STYLE="font-size:75%; vertical-align:top">3</SUP> NSCLC is the most common type of lung cancer representing <FONT STYLE="white-space:nowrap">~80-85%</FONT> of all diagnoses.<SUP STYLE="font-size:75%; vertical-align:top">4</SUP> The condition is
often diagnosed at a late stage, and less than 30% of patients are alive five years after diagnosis.<SUP STYLE="font-size:75%; vertical-align:top">5,6</SUP> There remains a high unmet need for additional treatment options for people living with
NSCLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of
Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">TACTI-004</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TACTI-004</FONT> (<B>T</B>wo <B>ACT</B>ive <B>I</B>mmunotherapies) is a randomised, double-blind, controlled Phase III study
evaluating eftilagimod alfa (efti), a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> MHC Class&nbsp;II agonist, in combination with MSD&#146;s (Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA) <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) and chemotherapy as first line therapy for patients with advanced or
metastatic <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer with no EGFR, ALK or ROS1 genomic tumour aberrations. The global trial will enrol approximately 756 patients regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT>
expression and with <FONT STYLE="white-space:nowrap">non-squamous</FONT> or squamous tumours at over 150 clinical sites in over 25 countries. Patients will be randomised 1:1 to receive either efti in combination with pembrolizumab and chemotherapy
in the treatment arm or pembrolizumab in combination with chemotherapy and placebo in the control arm. The study&#146;s dual primary endpoints are progression-free survival and overall survival. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a late-stage biotechnology
company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT
STYLE="white-space:nowrap">(LAG-3),</FONT> and its diversified product portfolio harnesses <FONT STYLE="white-space:nowrap">LAG-3&#146;s</FONT> ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to
bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Patients randomised 1:1 in <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> Phase II to receive 30mg or
90mg dosing of eft in combination with paclitaxel to determine the optimal biological dose consistent with the FDA&#146;s Project Optimus initiative. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>Immutep&#146;s Efti in Combination with
KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Generates Excellent Overall Survival Benefit in Patients with Metastatic <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer</U>, </I></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>October 2023, and <U>Immutep&#146;s Efti Shows Excellent Survival Data from <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> Trial in <FONT
STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer</U>, November 2024 </I></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>3.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>International Agency for Research on Cancer &#150; World Health Organization. Rates of trachea, bronchus and
lung cancer. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>4.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Zappa C&nbsp;&amp; Mousa <FONT STYLE="white-space:nowrap">Non-small</FONT> cell lung cancer: current
treatment and future advances, Transl Lung Cancer Res. 2016 Jun; 5(3): 288&#150;300. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>5.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Polanco D et al. Prognostic value of symptoms at lung cancer diagnosis: a three-year observational study. J
Thorac Dis 2021;13:1485&#150;1494. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>6.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) -
<U>https://seer.cancer.gov/statfacts/html/lungb.html</U> </I></P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g936071g92h95.jpg" ALT="LOGO" STYLE="width:2.27292in;height:0.742361in;">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Sodali&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>catherine.strong@sodali.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the Board of Immutep Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264
George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g936071g92h95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g936071g92h95.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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M^/GZ_]H # ,!  (1 Q$ /P#]_**:)E*[MPV^M'F+NV[OFZXH =1110 4444
M%%%% !1110 4444 %%%% !12,X4\TAD4?Q4 .HI%</G'8XI: "BBB@ HHHH
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M9XW_ &XM-\ ZA=:/)X?N/$-SIDB+8JLWE1F;;AQW_=CMS^-?=_C_ %6Z\.^
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7 -CC//.T'OTJ2BB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
